Antibody discovery at Antibody Engineering 2026
Dec 13–16, 2026 San Diego, CA ~900 attendees Website
68 organizations at Antibody Engineering 2026 present work in antibody discovery: 53 suppliers and service providers, 10 academic, government and non-profit bodies and 5 drug developers. Between them they bring 54 presentations to the program. Most represented: Genentech (3 on the program), Johnson & Johnson (3 on the program), University of Southampton (3 on the program). As of Nov 10, 2026.
Format
Top represented
Showing 1–13 of 68 organizations
| Organization | Antibody Engineering 2026 Attendance |
|---|---|
Genentech South San Francisco, CA | |
Biotechnology company and Roche Group member that discovers, develops and markets antibody and other medicines. | Talk Sun Dec 13 11:00am–11:45am Talk Mon Dec 14 2:30pm–3:00pm Dissecting the Mechanisms of Action of PROTABs: Insights into Designing Antibody-Based Protein Degraders How the shape of antibody binding decides whether a target protein on the cell surface is actually destroyed. Bispecifics & multispecifics Chair Tue Dec 15 8:10am–8:15am Talk Tue Dec 15 8:15am–8:45am From COVID to Cancer: LNP-mRNA as an Antigen Format for Antibody Discovery Against Challenging Membrane Proteins Immunizing animals with mRNA packaged in tiny fat particles, so their antibodies recognize proteins embedded in cell membranes. Protein engineering |
Johnson & Johnson New Brunswick, NJ | |
Healthcare company whose Innovative Medicine segment develops antibodies, bispecifics and other medicines. | Talk Sun Dec 13 2:15pm–2:45pm Format Matters: Biophysical Characterization and Developability of Complex Biotherapeutics How a molecule's overall shape changes whether it can be made into a drug, across many measured antibody formats. Talk Mon Dec 14 10:55am–11:30am Chair Tue Dec 15 8:10am–8:15am |
University of Southampton Southampton, United Kingdom | |
Public research university whose Centre for Cancer Immunology works on antibody immunotherapy and Fc receptor biology. | Chair Mon Dec 14 2:25pm–2:30pm Talk Mon Dec 14 4:45pm–5:15pm Disulfide Engineering of Immunostimulatory Antibodies for Augmented Receptor Agonism and Immune Cell Stimulation Adding chemical bridges between an antibody's two arms to lock its shape and make it switch on immune cells more strongly. Protein engineering Chair Tue Dec 15 8:10am–8:15am |
Alloy Therapeutics Waltham, MA | |
Provides ATX transgenic mice, display libraries and discovery services for antibodies and other drug modalities to drug developers. | Booth Exhibiting at Booth 220 Mon, Dec 144:00pm–4:45pmTue, Dec 159:45am–4:45pm Talk Mon Dec 14 1:45pm–2:15pm ATX-Gx Select: A New Mouse Strain That Can Identify Antigen Experienced B Cells in Situ to Facilitate Antibody Drug Discovery for Complex Therapeutic Targets New transgenic mouse strains that fluorescently mark antigen-experienced B cells, so antibodies against hard targets can be found without making the target protein. Antibody discovery Talk Wed Dec 16 7:30am–8:00am VHH and VLL Discovery Using ATX Transgenic Animals and Yeast Displayed Libraries Finding tiny single-piece human antibodies, using engineered mice and yeast-grown libraries, that can reach hidden pockets on a target. Antibody discovery |
Twist Bioscience South San Francisco, CA | |
Synthetic DNA company whose biopharma unit provides antibody libraries and antibody discovery and optimization services. | Booth Exhibiting at Booth 200 Mon, Dec 144:00pm–4:45pmTue, Dec 159:45am–4:45pm Talk Mon Dec 14 12:15pm–1:15pm Scaling Wet-Lab Validation for AI-based Biologic Discovery Why lab testing has become the bottleneck for AI antibody design, and how a shared model platform from Eli Lilly connects to it. AI & computational designAntibody discovery Talk Tue Dec 15 1:40pm–2:00pm Screening in the Format You’ll Develop In: Cell-Free Expression of Full-Length IgG Making full-length antibodies without cells at screening scale, and how their binding compares with the same antibodies made in mammalian cells. Antibody discovery Talk Wed Dec 16 7:30am–8:00am Engineering for Better Bispecifics: Introducing the B-Body® Platform A two-target antibody design meant to assemble reliably, avoiding low yields and hard purification when production scales up. Bispecifics & multispecificsDevelopability & CMC |
Fully human antibody discovery built on its Harbour Mice transgenic platforms for conventional and heavy-chain-only antibodies, offered as integrated discovery services. | Booth Exhibiting at Booth 203 Mon, Dec 144:00pm–4:45pmTue, Dec 159:45am–4:45pm Talk Mon Dec 14 1:45pm–2:15pm A Fully Human, AI-native Discovery and Development Platform for Next-generation Modality Solutions How fully human antibody mice combined with AI design feed immune cell engagers, brain-crossing antibodies, drug conjugates and other complex formats. Antibody discoveryAI & computational design Talk Tue Dec 15 11:30am–12:00pm VHH to Mice – With a Focus on In vivo Discovery/Screening Approaches for Therapeutic Discovery Applications Why single-domain human antibodies from engineered mice suit CAR-T cells and T-cell engagers, and how testing for target-cell killing picks better candidates. Bispecifics & multispecifics |
Harvard University Cambridge, MA | |
Private research university, including Harvard Medical School. | Talk Mon Dec 14 2:30pm–3:00pm Discovery of G protein-coupled Receptor Modulator Antibody Fragments Small antibody fragments that switch on or block the large family of signal-receiving proteins in cell membranes. Protein engineering Talk Wed Dec 16 8:15am–8:45am A New Homotypic Interface Expands Anti-Malarial Antibody Recognition Breadth Evolving a malaria antibody so copies of it grip each other in a new way and protect against more parasite strains. Beyond oncology |
University of Texas at Austin Austin, TX | |
Public research university in Austin, Texas. | Talk Mon Dec 14 5:15pm–5:45pm Computational Approaches for Antibody and TCR Modeling Design and Discovery AI & computational design Talk Tue Dec 15 10:30am–11:00am |
ATUM Newark, CA | |
Provides gene synthesis, protein expression and the Leap-In transposase system for stable cell line development. | Booth Exhibiting at Booth 309 Mon, Dec 144:00pm–4:45pmTue, Dec 159:45am–4:45pm Talk Mon Dec 14 1:15pm–1:45pm Accelerating Lead Generation: An Integrated End-to-End Antibody Discovery and Engineering Pipeline Moving from mouse immunization to humanized antibodies, then testing how well the leads convert into two-target formats, as one quick pipeline. Antibody discovery |
Contract research, development and manufacturing organization in India offering antibody discovery and biologics development and manufacturing. | Booth Exhibiting at Booth 421 Mon, Dec 144:00pm–4:45pmTue, Dec 159:45am–4:45pm Talk Tue Dec 15 1:20pm–1:40pm Discover, Express, De-Risk: Accelerating Antibodies from Single B Cells to Lead Candidates Linking single B-cell sorting to fast antibody production and lab tests that flag molecules likely to cause problems during development. Antibody discoveryDevelopability & CMC |
Provides recombinant antibody expression and production services, plus antibody discovery, for drug developers. | Booth Exhibiting at Booth 212 Mon, Dec 144:00pm–4:45pmTue, Dec 159:45am–4:45pm Talk Tue Dec 15 12:05pm–12:35pm Wet-lab data acquisition for rapid iteration of AI-powered macromolecular drugs Standardized lab data delivered in days, so the AI models designing millions of antibody candidates can be retrained more quickly. AI & computational design |
Provides custom genetically engineered mouse and rat models and related preclinical services, including humanized antibody-discovery mice. | Booth Exhibiting at Booth 411 Mon, Dec 144:00pm–4:45pmTue, Dec 159:45am–4:45pm Talk Tue Dec 15 9:50am–10:00am HUGO-Nano: A Human VHH Mouse Platform Engineered with Camelid Features Mice engineered to make fully human single-domain antibodies with camelid-like features, plus a case study on one aimed at the transferrin receptor. Antibody discovery |
FairJourney Biologics Porto, Portugal | |
Antibody discovery and engineering contract research organization using immunization, phage and other display technologies. | Booth Exhibiting at Booth 504 Mon, Dec 144:00pm–4:45pmTue, Dec 159:45am–4:45pm Talk Tue Dec 15 12:05pm–12:35pm Engineering Switch antibodies – the case of IL-12 A switchable antibody format that keeps the potent immune signal interleukin-12 inactive until it meets a protein found around tumors. Protein engineeringBispecifics & multispecifics |
Find buyers in antibody discovery
Tell us what you sell and we’ll find the people at organizations working on antibody discovery most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Browse Antibody Engineering 2026 by
Organization type
Topic
Exhibit hall
Everyone
Not affiliated with or endorsed by Antibody Engineering & Therapeutics, its organizers or The Antibody Society. Submit a correction